Loading…
Ensuring Equal Access to Treatments Act of 2015
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 3,548 other S bills in the 114th — cohort avg 43d
Ensuring Equal Access to Treatments Act of 2015 Amends title XVIII (Medicare) of the Social Security Act, with respect to the prospective payment system for hospital outpatient department (OPD) services, to direct the Secretary of Health and Human Services to create certain additional groups of covered OPD services that classify separately, from those that do not utilize such a drug, procedures that utilize a drug (other than contrast agents, diagnostic radiopharmaceutical, or anesthesia drugs) that both has a cost above the drug packaging threshold and functions as a supply when used in a diagnostic test or procedure.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (6)
2016 · third_quarter · Health Issues
Read twice and referred to the Committee on Finance.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to CMS Outpatient Prospective Payment System (OPPS) rule. H.R. 1178, Ensuring Equal Access to Treatments Act of 2015. S.1466, Ensuring Equal Access to Treatments Act of 2015. Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to CMS Outpatient Prospective Payment System (OPPS) rule. H.R. 1178, Ensuring Equal Access to Treatments Act of 2015. S.1466, Ensuring Equal Access to Treatments Act of 2015. Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Medicare/Medicaid
H.R. 1178, S. 1466, Ensuring Equal Access to Treatments Act of 2015: Medicare packaged payment reform.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Medicare/Medicaid
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512); Medicare Program; Part B Drug Payment Model, Proposed rule, CMS-1670-P (March 11, 2016) - Provisions related to the Medicare Part B Drug Payment Model; H.R. 5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models - Suspending the Part B Drug Payment Model; Medicare Part D rebates policy issues.
Client expense: $740,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Medicare/Medicaid
Support of H.R. 1178/S. 1466, the Ensuring Equal Access to Treatments Act of 2015; advocacy in support of Medicare coverage for outpatient cancer drugs
Client expense: Not reported · Firm income: $27,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Medicare/Medicaid
Support of H.R. 1178/S. 1466, the Ensuring Equal Access to Treatments Act of 2015; reimbursement of outpatient medications
Client expense: Not reported · Firm income: $75,000
Government targets: HOUSE OF REPRESENTATIVES
2016 · fourth_quarter · Health Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to CMS Outpatient Prospective Payment System (OPPS) rule. H.R. 1178, Ensuring Equal Access to Treatments Act of 2015. S.1466, Ensuring Equal Access to Treatments Act of 2015. Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517). Issues related to drug pricing.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Medicare/Medicaid
Advocated for Medicare packaged payment reform. Advocated for the Ensuring Equal Access to Treatments Act (H.R. 1178 / S. 1466), to protect patient access to lifesaving medical procedures and breakthrough eye surgery.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Medical/Disease Research/Clinical Labs
Advocated for Medicare packaged payment reform. Advocated for the Ensuring Equal Access to Treatments Act (H.R. 1178 / S. 1466), to protect patient access to lifesaving medical procedures and breakthrough eye surgery.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Medicare/Medicaid
H.R. 1178, S. 1466, Ensuring Equal Access to Treatments Act of 2015: Medicare packaged payment reform.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Medicare/Medicaid
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512); Medicare Program; Part B Drug Payment Model, Proposed rule, CMS-1670-P (March 11, 2016) - Provisions related to the Medicare Part B Drug Payment Model; H.R. 5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models - Suspending the Part B Drug Payment Model; Medicare Part D rebates policy issues.
Client expense: $420,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to CMS Outpatient Prospective Payment System (OPPS) rule. H.R. 1178, Ensuring Equal Access to Treatments Act of 2015. S.1466, Ensuring Equal Access to Treatments Act of 2015. Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Medicare/Medicaid
Support of H.R. 1178/S. 1466, the Ensuring Equal Access to Treatments Act of 2015; advocacy in support of Medicare coverage for outpatient cancer drugs
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Medicare/Medicaid
Support of H.R. 1178/S. 1466, the Ensuring Equal Access to Treatments Act of 2015; reimbursement of outpatient medications
Client expense: Not reported · Firm income: $75,000
Government targets: HOUSE OF REPRESENTATIVES
2016 · third_quarter · Health Issues
HR.1178 and S.1466, Ensuring Equal Access to Treatments Act; HR 2739, Cancer Drug Coverage Parity Act of 2015; Issues related to P.L. 96-517, the Bayh-Dole Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Medicare/Medicaid
Advocated for Medicare packaged payment reform. Advocated for the Ensuring Equal Access to Treatments Act (H.R. 1178 / S. 1466), to protect patient access to lifesaving medical procedures and breakthrough eye surgery. Advocated for improvements to FDA approval process.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Medical/Disease Research/Clinical Labs
Advocated for Medicare packaged payment reform. Advocated for the Ensuring Equal Access to Treatments Act (H.R. 1178 / S. 1466), to protect patient access to lifesaving medical procedures and breakthrough eye surgery. Advocated for improvements to FDA approval process.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Medicare/Medicaid
H.R. 1178, S. 1466, Ensuring Equal Access to Treatments Act of 2015: Medicare packaged payment reform.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Medicare/Medicaid
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Client expense: $680,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Health Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to CMS Outpatient Prospective Payment System (OPPS) rule. H.R. 1178, Ensuring Equal Access to Treatments Act of 2015. S.1466, Ensuring Equal Access to Treatments Act of 2015. Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Medicare/Medicaid
Support of H.R. 1178/S. 1466, the Ensuring Equal Access to Treatments Act of 2015; advocacy in support of Medicare coverage for outpatient cancer drugs
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Medicare/Medicaid
Support of H.R. 1178/S. 1466, the Ensuring Equal Access to Treatments Act of 2015; reimbursement of outpatient medications
Client expense: Not reported · Firm income: $75,000
Government targets: HOUSE OF REPRESENTATIVES
2016 · second_quarter · Health Issues
HR.1178 and S.1466, Ensuring Equal Access to Treatments Act; HR 2739, Cancer Drug Coverage Parity Act of 2015; Issues related to P.L. 96-517, the Bayh-Dole Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Medical/Disease Research/Clinical Labs
Advocated for Medicare packaged payment reform. Advocated for the Ensuring Equal Access to Treatments Act (H.R. 1178 / S. 1466), to protect patient access to lifesaving medical procedures and breakthrough eye surgery.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Medicare/Medicaid
Advocated for Medicare packaged payment reform. Advocated for the Ensuring Equal Access to Treatments Act (H.R. 1178 / S. 1466), to protect patient access to lifesaving medical procedures and breakthrough eye surgery.
Client expense: Not reported · Firm income: $45,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Medicare/Medicaid
H.R. 1178, S. 1466, Ensuring Equal Access to Treatments Act of 2015: Medicare packaged payment reform.
Client expense: Not reported · Firm income: Not reported
2016 · first_quarter · Medicare/Medicaid
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Client expense: $680,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Medicare/Medicaid
Support of H.R. 1178/S. 1466, the Ensuring Equal Access to Treatments Act of 2015; advocacy in support of Medicare coverage for outpatient cancer drugs
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Medicare/Medicaid
Support of H.R. 1178/S. 1466, the Ensuring Equal Access to Treatments Act of 2015; reimbursement of outpatient medications
Client expense: Not reported · Firm income: $70,000
Government targets: HOUSE OF REPRESENTATIVES
2016 · first_quarter · Health Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to CMS Outpatient Prospective Payment System (OPPS) rule. H.R. 1178, Ensuring Equal Access to Treatments Act of 2015. S.1466, Ensuring Equal Access to Treatments Act of 2015. Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Medical/Disease Research/Clinical Labs
Advocated for Medicare packaged payment reform. Advocated for the Ensuring Equal Access to Treatments Act (H.R. 1178 / S. 1466), to protect patient access to lifesaving medical procedures and breakthrough eye surgery.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Medicare/Medicaid
Advocated for Medicare packaged payment reform. Advocated for the Ensuring Equal Access to Treatments Act (H.R. 1178 / S. 1466), to protect patient access to lifesaving medical procedures and breakthrough eye surgery.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Health Issues
HR.1178 and S.1466, Ensuring Equal Access to Treatments Act; HR 2739, Cancer Drug Coverage Parity Act of 2015; Issues related to P.L. 96-517, the Bayh-Dole Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · third_quarter · Medicare/Medicaid
Support of H.R. 1178/S. 1466, the Ensuring Equal Access to Treatments Act of 2015; advocacy in support of Medicare coverage for outpatient cancer drugs
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Medicare/Medicaid
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Client expense: $680,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Health Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to CMS Outpatient Prospective Payment System (OPPS) rule. H.R. 1178, Ensuring Equal Access to Treatments Act of 2015. S.1466, Ensuring Equal Access to Treatments Act of 2015.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Health Issues
HR.1178 and S.1466, Ensuring Equal Access to Treatments Act; HR 2739, Cancer Drug Coverage Parity Act of 2015
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Medicare/Medicaid
Support of H.R. 1178/S. 1466, the Ensuring Equal Access to Treatments Act of 2015; reimbursement of outpatient medications
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Medicare/Medicaid
Support of H.R. 1178/S. 1466, the Ensuring Equal Access to Treatments Act of 2015; advocacy in support of Medicare coverage for outpatient cancer drugs
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Medicare/Medicaid
The Ensuring Equal Access to Treatments Act (H.R. 1178 / S. 1466), to protect patient access to lifesaving medical procedures and breakthrough eye surgery.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Medical/Disease Research/Clinical Labs
The Ensuring Equal Access to Treatments Act (H.R. 1178 / S. 1466), to protect patient access to lifesaving medical procedures and breakthrough eye surgery.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · third_quarter · Health Issues
HR.1178 and S.1466, Ensuring Equal Access to Treatments Act; HR.6, 21st Century Cures Act; HR 2739, Cancer Drug Coverage Parity Act of 2015
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · third_quarter · Medicare/Medicaid
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Client expense: $680,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · third_quarter · Health Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to CMS Outpatient Prospective Payment System (OPPS) rule. H.R. 1178, Ensuring Equal Access to Treatments Act of 2015. S.1466, Ensuring Equal Access to Treatments Act of 2015.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · third_quarter · Medicare/Medicaid
Support of H.R. 1178/S. 1466, the Ensuring Equal Access to Treatments Act of 2015; advocacy in support of Medicare coverage for outpatient cancer drugs
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · third_quarter · Medicare/Medicaid
Support of H.R. 1178/S. 1466, the Ensuring Equal Access to Treatments Act of 2015; reimbursement of outpatient medications
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · third_quarter · Medical/Disease Research/Clinical Labs
The Ensuring Equal Access to Treatments Act (H.R. 1178 / S. 1466), to protect patient access to lifesaving medical procedures and breakthrough eye surgery.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · second_quarter · Health Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to CMS Outpatient Prospective Payment System (OPPS) rule. H.R. 1178, Ensuring Equal Access to Treatments Act of 2015. S.1466, Ensuring Equal Access to Treatments Act of 2015.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · second_quarter · Medicare/Medicaid
Support of H.R. 1178/S. 1466, the Ensuring Equal Access to Treatments Act of 2015; advocacy in support of Medicare coverage for outpatient cancer drugs
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · second_quarter · Medicare/Medicaid
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Client expense: $710,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| Republican |
| KS |
| Richard Burr | Republican | NC |
| Richard J. Durbin | Democratic | IL |
| Rob Portman | Republican | OH |
| Robert Menendez | Democratic | NJ |
| Thomas R. Carper | Democratic | DE |